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Although inflammation is involved in the development of atrial fibrillation (AF), the associa-
tion of white blood cell (WBC) count and differential with AF has not been thoroughly exam-
ined in large cohorts with extended follow-up.
Methods
We studied 14,500 men and women (25% blacks, 55% women, mean age 54) free of AF at
baseline (1987–89) from the Atherosclerosis Risk in Communities (ARIC) study, a commu-
nity-based cohort in the United States. Incident AF cases through 2010 were identified from
study electrocardiograms, hospital discharge records and death certificates. Multivariable
Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% con-
fidence intervals (CI) for AF associated with WBC count and differential.
Results
Over a median follow-up time of 21.5 years for the entire cohort, 1928 participants had inci-
dent AF. Higher total WBC count was associated with higher AF risk independent of AF risk
factors and potential confounders (HR 1.09, 95% CI 1.04–1.15 per 1-standard deviation
[SD] increase). Higher neutrophil and monocyte counts were positively associated with AF
risk, while an inverse association was identified between lymphocyte count and AF
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(multivariable adjusted HRs 1.16, 95% CI 1.09–1.23; 1.05, 95% CI 1.00–1.11; 0.91, 95% CI
0.86–0.97 per 1-SD, respectively). No significant association was identified between eosin-
ophils or basophils and AF.
Conclusions
High total WBC, neutrophil, and monocyte counts were each associated with higher AF risk
while lymphocyte count was inversely associated with AF risk. Systemic inflammation may
underlie this association and requires further investigation for strategies to prevent AF.
Introduction
Atrial fibrillation (AF) is a growing health concern in the United States. Currently, over two
million individuals have AF, and its prevalence is anticipated to double by 2050.[1] In addition
to being the most frequently observed sustained cardiac arrhythmia in clinical practice, AF has
been linked with increased risk of cardiovascular disease (CVD), heart failure (HF), myocardial
infarction (MI), stroke, and overall mortality.[2–5] However, a considerable proportion of the
attributable risk of AF (44%) remains unexplained after accounting for one or more borderline
or elevated risk factors.[6]
Higher levels of systemic inflammation, usually determined with C-reactive protein, have
been associated with AF risk.[7,8] White blood cell (WBC) count can also be considered a bio-
marker of inflammation and potentially related to an increased risk of AF. In selected patient
samples, an elevated WBC count during the perioperative period was identified as being pre-
dictive of postoperative AF[9–12] and with recurrent AF after pulmonary vein isolation.[13]
The association between WBC count and AF in the general population has been examined pre-
viously in a subset of the Framingham Heart Study and a study in Norway. Among 936 eligible
participants followed up for a maximum of 5 years in the Framingham Heart Study, higher
WBC count was associated with increased risk of AF. However, this association was no longer
significant after additional follow up.[14] In Norway, the Tromsø study also identified a posi-
tive association between total WBC count and AF risk, while there was no association between
WBC differential with AF risk.[15] However, granulocyte count (especially neutrophils) has
been linked to increased incidence of other CVD,[16,17] and evidence suggests that myeloper-
oxidase (MPO), an enzyme abundantly produced by neutrophils, may be involved in the devel-
opment of atrial fibrosis, resulting in an increased risk of AF.[18,19] Therefore, studying the
association of WBC differential counts with AF in a larger sample size and in a racially diverse
population might clarify the association of WBC and its differential with AF.
We prospectively examined the relationship between total WBC count with incident AF in
the Atherosclerosis Risk in Communities (ARIC) Study, a community-based cohort that
included a large sample of middle-aged participants, followed for an extended period. Also, we
explored the association between each component of WBC differential and AF incidence sepa-
rately. Overall, we hypothesized that individuals with higher WBC count would have an
increased risk for AF, and this association was due to an increased risk of AF associated with
higher levels of granulocytes, mainly neutrophils.
Methods
Study Design and Subjects
The ARIC study is a prospective, community-based cohort that aimed to explore risk factors of
atherosclerosis and CVD.[20] Briefly, a total of 15,792 men and women aged 45–64 years
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located in four communities from around the United States (Forsyth County, North Carolina;
Jackson, Mississippi; the northwest suburbs of Minneapolis, Minnesota; and Washington
County, Maryland) were recruited at the baseline examination in 1987–1989 (visit 1), which
included a home interview and a clinical visit. Additional study examinations occurred in
1990–1992 (visit 2), 1993–1995 (visit 3), 1996–1998 (visit 4), and 2011–2013 (visit 5). This
cohort consists of African Americans from Jackson, mostly whites fromMinneapolis and
Washington County, and both African Americans and whites from Forsyth County. The Uni-
versity of Minnesota Institutional Review Board approved the present study, and all partici-
pants enlisted in the study have given their written informed consent.
From the initial ARIC sample of 15,792 individuals, the following participants were
excluded: those with races other than white or African-American due to small sample sizes
(n = 48); African Americans who were located in either Minneapolis or Washington County
due to small sample sizes (n = 55); those with prevalent AF or atrial flutter diagnosed by elec-
trocardiograms (ECG) at baseline (n = 37); those with a missing or an unreadable baseline
ECG (n = 309); those who were missing baseline WBC count measurements (n = 223); those
with total WBC counts less than 3 x 109/L (one percentile) or greater than 12 x 109/L (99th per-
centile) due to a concern for other occult diseases that may affect WBC count (n = 283); and
those who were missing any information on other covariates (n = 337). Overall, the final ana-
lytic samples consisted of 14,500 participants for the total WBC analyses (Fig 1). The WBC dif-
ferential analyses have a reduced sample size (n = 10,661) since individual WBC differential
measurements were not available for all ARIC participants.
Assessment of Total WBC Count/Differential and Other Covariates
Fasting blood samples were drawn from the antecubital vein, and plasma and serum were fro-
zen at -70°C until they were analyzed. WBCs were retrieved from whole anti-coagulated blood,
and WBC count was determined by automated particle Coulter Counters within 24 hours after
venipuncture in local hospital hematology laboratories. Total WBC count was determined in
the whole blood sample. The reliability coefficient for the WBC count measurement was
greater than 0.96.[21] Fibrinogen plasma levels were determined in the ARIC Central Hemo-
stasis Laboratory using the thrombin time titration method with reagents obtained from Gen-
eral Diagnostics Organon Technica Co. (Morris Plains, New Jersey) from previously
established procedures.[22] Measurements repeated on a sample of participants over several
weeks yielded reliability coefficients of 0.72 for fibrinogen.[23] Serum albumin was measured
with a Coulter DACOS instrument (Coulter Diagnostics, Hialeah, Florida) with a bromcresol
green colorimetric assay.[24] The reliability coefficient of albumin measurements based on
repeated testing of 40 healthy participants over four weeks was 0.69, and the within-person var-
iability was 2.8 percent.[25]
Questionnaires were used at each study exam to assess self-reported information such as
smoking status, pack-years, drinking status, education level, and medication usage. Pack-years
were calculated by the average number of cigarettes per day divided by 20 cigarettes per pack
and then multiplied by the number of years smoked. In addition, all medications including
antihypertensives used in the preceding 2 weeks before each clinic visit were documented.
Seated blood pressure was measured after five minutes of rest using a random-zero sphygmo-
manometer, and systolic blood pressure was defined as the average of the last 2 of 3 consecutive
measurements. Height and weight were measured while the individual was wearing a scrub suit
and no shoes, and body mass index (BMI) was defined as weight in kilograms divided by height
in meters squared. Chronic obstructive pulmonary disease (COPD) was determined through a
self-reported physician diagnosis of chronic bronchitis or emphysema. Prevalent diabetes
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mellitus was characterized by a fasting glucose126 mg/dL, non-fasting glucose200 mg/dL,
a self-reported physician diagnosis, or use of anti-diabetic medications. Prevalent MI at base-
line was characterized by a previously reported MI event or from ECG while prevalent HF was
defined by the intake of HF medications or a score of 3 on the Gothenburg criteria.[26] Preva-
lent stroke was designated by a self-reported history of physician-diagnosed stroke. Incident
cases of HF, MI, or stroke were identified through study exams, annual telephone interviews,
and the ongoing surveillance of ARIC community hospitals for any hospitalizations or deaths
of any cohort participants.
Fig 1. Flow chart of participants excluded at baseline, Atherosclerosis Risk in Communities Study,
1987 to 1989. ECG = electrocardiogram. WBC =White Blood Cell.
doi:10.1371/journal.pone.0136219.g001
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Incident AF events
AF cases within the ARIC cohort have been ascertained from three sources: ECGs at each of
the five study exams, diagnostic codes from hospitalization discharge summaries, and death
certificates.[27,28] A 12-lead, 10-second ECG during each study visit was performed with each
participant lying in a supine position. After the ECGs were transmitted electronically to the
ARIC ECG Reading Center (EPICARE, Wake Forest University Health Sciences, Winston-
Salem, North Carolina), they were reviewed for technical quality and were electronically pro-
cessed using 2001 version of the GE Marquette 12-SL program (GE Healthcare, Milwaukee,
Wisconsin). A trained cardiologist visually rechecked and confirmed any ECGs that were auto-
matically coded as an AF or atrial flutter diagnosis.[29]
Hospitalizations and deaths in the ARIC study are identified through annual follow-up
phone calls to the study participants (>90% participation) and continuous surveillance of local
hospital discharge lists, the National Death Index, and state registries for any cardiovascular
events or deaths. Trained abstractors compile pertinent information from all participants’ hos-
pitalizations. Using International Classification of Diseases, ninth revision, clinical modifica-
tion (ICD-9-CM) codes for diagnoses and procedures associated with each hospitalization, AF
was identified when 427.31 or 427.32 was listed as a discharge diagnostic code in any hospitali-
zation. Any AF event identified during a hospitalization for open cardiac surgery was excluded.
In a physician review of discharge summaries from 125 possible AF cases within the ARIC
study, approximately 90% of the cases were confirmed, and the sensitivity was>80%.[27] For
AF ascertainment through death certifications, incident AF cases were determined as a cause of
death if ICD-9 code 427.3 or ICD-10 code I48 was listed. The vast majority of incident AF
cases (>98%) in this analysis were identified from hospitalization discharge codes, while less
than 1% of AF cases were identified from death certificates. AF incidence date was defined as
the first date in which an AF diagnosis by ECG, hospitalization, or death occurred.
Statistical Analysis
Baseline characteristics of participants stratified by total WBC count quintiles and then by sep-
arate WBC differential quintiles and groups are reported using means and standard deviations
(SD) for continuous variables and percentages for categorical variables. For the primary analy-
sis, Cox proportional hazards regression was used to calculate adjusted hazard ratios (HRs)
and 95% confidence interval (CI) for the association of total WBC count with incident AF. The
association of WBC differential count with incident AF was investigated in separate Cox
regression models for each component of WBC differential. Follow-up time was defined as the
time between the baseline visit and the date of AF incidence, death, loss to follow-up, or
December 31, 2010, whichever came first. Death and loss to follow-up were considered to be
censoring events with n = 3428 dying from causes other than AF and n = 591 being lost to fol-
low-up.
Initially, restricted cubic splines with knots at the 5th, 27.5th, 50th, 72.5th and 95th percentiles
were utilized to explore the shape of the dose-response association of total WBC count and
each WBC differential with AF risk. For the Cox regression analysis, total WBC count and all
WBC differential except basophils were classified as quintiles while basophils were classified as
3 groups due to the limited range. In addition, both total WBC andWBC differential were
modeled as linear variables per 1-SD unit change (total WBC count SD = 1.70 x 109/L, neutro-
phil count SD = 1.42 x 109/L, lymphocyte count SD = 0.64 x 109/L, neutrophil count/lympho-
cyte count ratio SD = 1.25, monocyte count SD = 0.18 x 109/L, eosinophil count SD = 0.15 x
109/L, and basophil count SD = 0.04 x 109/L). The initial model was adjusted for age, race, sex,
and ARIC field center site at baseline. The second model was further adjusted for other baseline
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variables including COPD (yes, no), diabetes (yes, no), drinking status (current, former,
never), education level (some high school or less, high school graduate/vocational school, col-
lege/graduate school), smoking status (current, former, never), use of antihypertensive medica-
tions (yes, no), prevalent MI (yes, no), prevalent HF (yes, no), prevalent stroke (yes, no), and
the following continuous variables: BMI (kg/m2), pack-years, height (cm), and systolic blood
pressure (mmHg). Lastly, the third model was adjusted for incident MI, HF, and stroke as
time-dependent covariates and potential mediators of the association between total WBC
count/differential and AF risk since they are risk factors for AF and may be on the causal
pathway.
Effect modification was evaluated by age, sex, race, BMI, and smoking conducting stratified
analysis and including multiplicative terms between the effect modifier and total WBC count.
The proportional hazards assumption was explored through the examination of an interaction
term between each WBC variable and follow-up time along with the inspection of log-negative
log survival curves; no departures from the assumption were observed. In a sensitivity analysis,
individuals who had an incident AF event within the first two years of follow-up from baseline
were excluded to avoid including potentially undetected prevalent AF cases as incident cases.
Also, other inflammatory markers measured at baseline (fibrinogen and albumin) were
included in Model 2 as an additional analysis to examine the effect of adjusting for other
inflammatory markers on the total WBC count/differential and incident AF associations. Addi-
tional analyses were performed to examine the impact of the competing risk of death in the
association between WBC and AF using competing-risk regression models[30] and to evaluate
the association of total WBC count and differential with AF cases ascertained by ECG and hos-
pitalization separately. Finally, an analysis restricting follow-up to the first 10 years of follow-
up was done to compare the results to previous studies that had similar follow-up periods. All
statistical analyses were performed using SAS v 9.2 (SAS Inc., Cary, North Carolina).
Results
At baseline, 14,500 participants between the ages of 45 and 64 were free of AF and met the
inclusion criteria for this analysis. Median (25th–75th percentile) total WBC count was 5.8 x
109/L (4.8 x 109/L–7.1 x 109/L) for the entire cohort. Table 1 shows the characteristics of the
ARIC participants by total WBC count quintiles. A positive association was seen with several
risk factors for CVD such as BMI, diabetes, smoking, antihypertensive medications, and
COPD, while lower total WBC counts were seen in females and in African Americans. Baseline
characteristics by quintiles of specific components of WBC differential are shown in Tables
A-F in S1 File.
Total WBC Count and AF Risk
A total of 1928 ARIC participants were classified as having an incident AF event through Decem-
ber 31, 2010, with a median follow-up of 21.5 years for the whole study population. After adjust-
ment for age, race, and sex, total WBC count was positively and linearly associated with AF
incidence (Fig 2). In Table 2 (model 2), participants in the highest total WBC count quintile
(7.5–12.0 x 109/L) had a 23% higher AF risk than those in the lowest quintile (3.0–4.6 x 109/L)
after adjustment for AF risk factors and potential confounders (HR: 1.23; 95% CI: 1.05–1.44).
When total WBC count was modeled as a linear variable in an adjusted model, a 1-SD increase
in total WBC count was associated with a 9% higher risk of incident AF (HR: 1.09; 95% CI: 1.04–
1.15; Table 2, model 2). Adjustment for incident CVD as a time-varying covariate (Table 2,
model 3) weakened the total WBC count-incident AF association to non-significance in both the
quintile and linear results. There were no interactions by age, sex, race, BMI, and smoking.
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WBCDifferential Count and AF Risk
Table 3 shows the associations of each components of WBC differential count (as quintiles/
groups and as a 1-SD linear variable) with incident AF. Neutrophil count was positively and
linearly associated with AF risk after adjustment for age, race, and sex (Fig 3A). Comparing
those in the highest quintile (4.56–9.76 x 109/L) to those in the lowest quintile (0.22–2.30 x
109/L), the adjusted HR for AF potential confounders and a history of CVD was 1.57 (95% CI:
1.28–1.93) (Table 3, model 2). In contrast, lymphocyte count showed a weak, inverse associa-
tion with AF risk (Fig 3B). After adjustment (Table 3, model 2), the inverse association was
strengthened, and those in the highest quintile (>2.44–6.08 x 109/L) had a 30% reduced risk of
AF than those in the lowest quintile (0.09–1.44 x 109/L) (HR: 0.70, 95% CI: 0.58–0.84). The
neutrophil count/lymphocyte count ratio was positively associated with AF risk (Fig 3C). In
Table 3 (model 2), those in the highest neutrophil/lymphocyte ratio quintile (2.57–53.0) had a
HR of 1.70 (95% CI: 1.39–2.08) when compared to those in the lowest quintile (0.07–1.18)
after adjustment for AF risk factors and a history of CVD. In the fully adjusted model for neu-
trophil count, lymphocyte count, and neutrophil/lymphocyte ratio (Table 3, model 3), the
Table 1. Baseline characteristics by total white blood cell (WBC) count quintile, Atherosclerosis Risk in Communities Study, 1987 to 1989.
Total WBC Count (x 109/L)†
3.0–4.6 4.7–5.4 5.5–6.2 6.3–7.4 7.5–12.0
(n = 2970) (n = 2966) (n = 2769) (n = 3002) (n = 2793)
Total WBC count median, x 109/L 4.1 5.1 5.8 6.8 8.5
Age, years 53.9 (5.6) 54.1 (5.7) 54.3 (5.7) 54.4 (5.9) 54.1 (5.8)
Females, % 59.5 57.2 54.0 53.1 50.4
African Americans, % 37.4 26.8 20.9 20.3 18.4
Body mass index, kg/m2 26.9 (5.0) 27.4 (5.1) 27.9 (5.3) 28.2 (5.5) 28.0 (5.6)
Chronic obstructive pulmonary disease, % 5.9 7.5 9.8 11.0 13.5
Current drinker, % 51.8 56.8 58.5 56.8 59.6
Current smoker, % 10.1 14.6 18.8 30.4 55.0
Pack-years 8.6 (16.8) 11.1 (17.7) 14.4 (20.2) 19.3 (23.1) 27.3 (24.9)
Diabetes, % 7.1 8.7 11.6 13.7 17.0
Height, cm 168.4 (9.3) 168.4 (9.3) 168.7 (9.3) 168.4 (9.4) 168.7 (9.2)
High school degree, % 39.2 40.4 42.5 42.0 42.7
Systolic BP, mmHg 119.8 (18.5) 121.1 (18.6) 121.5 (18.3) 121.8 (19.1) 121.4 (19.0)
Use of antihypertensive medications, % 26.5 27.8 29.9 32.5 34.4
Prevalent heart failure, % 2.5 3.7 3.7 5.3 7.2
Prevalent myocardial infarction, % 2.3 2.6 4.4 4.5 6.3
Prevalent stroke, % 1.7 1.4 1.6 2.1 2.2
Basophil count, x 109/L* 0.03 (0.03) 0.03 (0.03) 0.03 (0.04) 0.04 (0.05) 0.04 (0.06)
Eosinophil count, x 109/L* 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) 0.2 (0.1) 0.2 (0.2)
Lymphocyte count, x 109/L* 1.6 (0.4) 1.8 (0.5) 1.9 (0.5) 2.1 (0.6) 2.5 (0.7)
Monocyte count, x 109/L* 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.4 (0.2) 0.5 (0.2)
Neutrophil count, x 109/L* 2.0 (0.6) 2.7 (0.6) 3.3 (0.6) 4.0 (0.7) 5.5 (1.2)
Neutrophil/lymphocyte ratio* 1.5 (0.7) 1.7 (1.1) 1.9 (0.9) 2.1 (1.3) 2.6 (1.7)
BP indicates blood pressure. Values are mean (SD) when appropriate.
*Reduced sample size: n = 10,661
†All baseline characteristics have p-values <0.05 for differences in means (ANOVA) and percentages (Chi-Square) between total WBC quintiles except
for height and prevalent stroke.
doi:10.1371/journal.pone.0136219.t001
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Fig 2. Association between total white blood cell count and incident atrial fibrillation presented as hazard ratio (solid line) and 95% confidence
intervals (shaded area), Atherosclerosis Risk in Communities Study, 1987 to 2010. *Cox proportional hazards model using restricted cubic splines with
knots at the 5th, 27.5th, 50th, 72.5th and 95th percentiles and adjustment for age, race, and sex. The reference is the median value of the total white blood cell
count (hazard ratio = 1), and the histogram represents the frequency distribution of the total white blood cell count in the study sample.
doi:10.1371/journal.pone.0136219.g002
Table 2. Hazard ratio (HR) and 95% confidence interval (CI) of atrial fibrillation (AF) by total white blood cell (WBC) count, Atherosclerosis Risk in
Communities Study, 1987 to 2010.
Total WBC Count (x 109/L)
3.0–4.6 4.7–5.4 5.5–6.2 6.3–7.4 7.5–12.0 Linear
(n = 2970) (n = 2966) (n = 2769) (n = 3002) (n = 2793) (per 1-SD* Increase)
AF Cases 300 326 377 453 472 1928
Person-years 58,663 57,492 52,712 54,358 48,137 271,362
Crude Incidence Rate (per 1000 person-years) 5.1 5.7 7.2 8.3 9.8 7.1
Model 1 HR 1 1.08 1.33 1.59 1.97 1.28
(95% CI) (Reference) (0.92–1.26) (1.14–1.55) (1.37–1.84) (1.70–2.28) (1.23–1.34)
Model 2 HR 1 0.99 1.08 1.16 1.23 1.09
(95% CI) (Reference) (0.84–1.16) (0.93–1.26) (1.00–1.36) (1.05–1.44) (1.04–1.15)
Model 3 HR 1 0.99 1.03 1.05 1.07 1.03
(95% CI) (Reference) (0.84–1.16) (0.88–1.20) (0.90–1.23) (0.91–1.26) (0.98–1.08)
Model 1: Cox proportional hazards model adjusted for age, race, sex, and study site.
Model 2: Model 1 with additional adjustment for body mass index, chronic obstructive pulmonary disease, diabetes mellitus, drinking status, educational
level, height, pack-years, smoking status, systolic blood pressure, use of antihypertensive medications, and prevalent heart failure, myocardial infarction,
or stroke at baseline.
Model 3: Model 2 with additional adjustment for heart failure, myocardial infarction, or stroke as time-varying covariates.
*Total WBC Count SD = 1.70 x 109/L
doi:10.1371/journal.pone.0136219.t002
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Table 3. Hazard ratio (HR) and 95% confidence interval (CI) of atrial fibrillation (AF) by white blood cell differential count, Atherosclerosis Risk in
Communities Study, 1987 to 2010.
Neutrophil Count (x 109/L)
0.22–2.30 >2.30–2.96 2.97–3.60 3.61–4.55 4.56–9.76 Linear
(n = 2141) (n = 2140) (n = 2116) (n = 2132) (n = 2132) (per 1-SD* Increase)
AF Cases 186 224 249 291 364 1314
Model 1 HR 1 1.19 1.34 1.62 2.27 1.32
(95% CI) (Reference) (0.97–1.45) (1.09–1.63) (1.33–1.97) (1.87–2.75) (1.25–1.39)
Model 2 HR 1 1.12 1.17 1.28 1.57 1.16
(95% CI) (Reference) (0.92–1.38) (0.95–1.44) (1.05–1.57) (1.28–1.93) (1.09–1.23)
Model 3 HR 1 1.12 1.09 1.20 1.36 1.09
(95% CI) (Reference) (0.91–1.37) (0.89–1.34) (0.98–1.47) (1.11–1.67) (1.02–1.15)
Lymphocyte Count (x 109/L)
0.09–1.44 >1.44–1.74 >1.74–2.03 >2.03–2.44 >2.44–6.08 Linear
(n = 2149) (n = 2123) (n = 2141) (n = 2120) (n = 2128) (per 1-SD* Increase)
AF Cases 282 252 271 279 230 1314
Model 1 HR 1 0.91 0.99 1.10 0.99 1.03
(95% CI) (Reference) (0.77–1.08) (0.84–1.18) (0.93–1.30) (0.83–1.18) (0.98–1.09)
Model 2 HR 1 0.87 0.88 0.90 0.70 0.91
(95% CI) (Reference) (0.74–1.04) (0.75–1.05) (0.76–1.06) (0.58–0.84) (0.86–0.97)
Model 3 HR 1 0.86 0.86 0.83 0.67 0.90
(95% CI) (Reference) (0.72–1.02) (0.72–1.01) (0.70–0.99) (0.56–0.81) (0.84–0.95)
Neutrophil Count/Lymphocyte Count Ratio
0.07–1.18 >1.18–1.58 1.59–2.02 2.03–2.56 2.57–53.0 Linear
(n = 2140) (n = 2124) (n = 2238) (n = 2044) (n = 2115) (per 1-SD* Increase)
AF Cases 184 231 253 306 340 1314
Model 1 HR 1 1.24 1.24 1.70 1.92 1.08
(95% CI) (Reference) (1.02–1.53) (1.01–1.53) (1.39–2.08) (1.58–2.35) (1.05–1.11)
Model 2 HR 1 1.21 1.22 1.58 1.70 1.07
(95% CI) (Reference) (0.99–1.48) (0.99–1.50) (1.29–1.93) (1.39–2.08) (1.04–1.10)
Model 3 HR 1 1.23 1.22 1.46 1.63 1.07
(95% CI) (Reference) (1.00–1.51) (0.99–1.51) (1.19–1.80) (1.33–2.00) (1.04–1.11)
Monocyte Count (x 109/L)
0–0.22 >0.22–0.29 0.30–0.37 >0.37–0.48 >0.48–3.72 Linear
(n = 2149) (n = 2116) (n = 2145) (n = 2179) (n = 2072) (per 1-SD* Increase)
AF Cases 212 242 283 279 298 1314
Model 1 HR 1 1.11 1.29 1.22 1.47 1.14
(95% CI) (Reference) (0.93–1.34) (1.08–1.54) (1.02–1.46) (1.23–1.75) (1.08–1.19)
Model 2 HR 1 1.13 1.25 1.12 1.16 1.05
(95% CI) (Reference) (0.94–1.36) (1.04–1.49) (0.93–1.34) (0.97–1.40) (1.00–1.11)
Model 3 HR 1 1.20 1.28 1.07 1.10 1.02
(95% CI) (Reference) (0.99–1.44) (1.07–1.53) (0.90–1.29) (0.92–1.32) (0.97–1.08)
Eosinophil Count (x 109/L)
0 0.01–0.09 >0.09–0.15 >0.15–0.23 >0.23–3.16 Linear
(n = 2287) (n = 1983) (n = 2137) (n = 2135) (n = 2119) (per 1-SD* Increase)
AF Cases 257 219 245 284 309 1314
Model 1 HR 1 1.06 1.02 1.25 1.38 1.09
(95% CI) (Reference) (0.87–1.29) (0.84–1.24) (1.03–1.52) (1.14–1.67) (1.04–1.13)
Model 2 HR 1 1.13 1.04 1.16 1.22 1.05
(Continued)
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adjusted HRs for both the quintiles and linear results remained significant though slightly
attenuated.
Both monocytes and eosinophils had positive associations with incident AF after adjust-
ment for demographics (Fig 3D and 3E). With further adjustment for AF risk factors including
CVD history (Table 3, model 2), eosinophils had a positive association with incident AF where
the HR of AF for the highest quintile compared to the lower quintile was 1.22 (95% CI: 1.01–
1.48). The monocyte-AF association comparing the highest to lowest quintile was attenuated
to non-significance. No association was observed between basophil count and AF risk after
adjustment for AF risk factors and potential confounders including history of CVD (Table 3,
model 2).
Sensitivity Analyses
We conducted five additional sensitivity analyses. First, those with incident AF events within
the first two years of follow-up from baseline were excluded (n = 52). Overall, the HRs for both
total WBC count and WBC differential count with incident AF were of a similar magnitude to
those seen in the models including all of the incident AF cases in both the quintile and linear
results (results not shown). Secondly, fibrinogen and albumin were added to a multivariate
model including multiple AF potential confounders and a history of CVD. Additional adjust-
ment for fibrinogen and albumin at baseline further attenuated the associations between total
WBC count and AF risk (HR of AF for the highest to lowest quintile: 1.15; 95% CI: 0.98–1.35;
HR per 1-SD linear change: 1.06; 95% CI: 1.01–1.12; Table G in S1 File). High fibrinogen and
low albumin were each associated with AF after adjustment for total WBC count (HR of AF for
fibrinogen per 1-SD linear change: 1.09; 95% CI: 1.04–1.14; HR of albumin per 1-SD linear
change: 0.89; 95% CI: 0.85–0.94). However, the HRs for each of the WBC differential count-AF
associations with adjustment for fibrinogen and albumin were of a similar magnitude to the
Table 3. (Continued)
(95% CI) (Reference) (0.93–1.38) (0.85–1.27) (0.95–1.40) (1.01–1.48) (1.00–1.10)
Model 3 HR 1 1.18 1.06 1.17 1.18 1.03
(95% CI) (Reference) (0.97–1.44) (0.87–1.30) (0.97–1.43) (0.98–1.44) (0.98–1.09)
Basophil Count (x 109/L)
0 0.01–0.05 >0.05–0.62 Linear
(n = 5450) (n = 1763) (n = 3448) (per 1-SD* Increase)
AF Cases 670 169 475 1314
Model 1 HR 1 0.72 1.09 1.04
(95% CI) (Reference) (0.60–0.85) (0.97–1.23) (0.98–1.10)
Model 2 HR 1 0.87 0.99 0.99
(95% CI) (Reference) (0.73–1.04) (0.88–1.12) (0.94–1.05)
Model 3 HR 1 0.94 0.97 0.99
(95% CI) (Reference) (0.79–1.13) (0.86–1.10) (0.94–1.04)
Model 1: Cox proportional hazards model adjusted for age, race, sex, and study site.
Model 2: Model 1 with additional adjustment for body mass index, chronic obstructive pulmonary disease, diabetes mellitus, drinking status, educational
level, height, pack-years, smoking status, systolic blood pressure, use of antihypertensive medications, and prevalent heart failure, myocardial infarction,
or stroke at baseline.
Model 3: Model 2 with additional adjustment for heart failure, myocardial infarction, or stroke as time-varying covariates.
*Neutrophil Count SD = 1.42 x 109/L, Lymphocyte Count SD = 0.64 x 109/L, Neutrophil/Lymphocyte Ratio SD = 1.25; Monocyte Count SD = 0.18
x 109/L, Eosinophil Count SD = 0.15 x 109/L, Basophil Count SD = 0.04 x 109/L
doi:10.1371/journal.pone.0136219.t003
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models without fibrinogen and albumin (Table G in S1 File). Third, an additional analysis
accounting for the competing risk of death was performed, with the results being comparable
to the main results (Table H in S1 File). Fourth, AF ascertainment results separated by ECG
and hospitalization cases followed similar directionality as the main results (Table I in S1 File).
Finally, restricting follow-up to the first ten years resulted in HRs for both total WBC count
andWBC differential count with incident AF being of a similar magnitude in both the quintile
and linear results (results not shown).
Discussion
In this prospective analysis of the ARIC cohort, a positive linear association between total
WBC count and incident AF was identified, with the highest risk of AF in individuals at the
higher end of the distribution of total WBC count. This association was greatly attenuated after
further adjustment for risk factors of AF but remained significant, which is similar to previous
literature examining this association in the general population.[14,15] For WBC differential,
elevated neutrophil and monocyte counts were positively associated with AF risk while an
inverse association was identified between lymphocyte count and AF after adjustment. A
Fig 3. Association between each white blood cell differential count and incident atrial fibrillation presented as hazard ratio (solid line) and 95%
confidence intervals (shaded area), Atherosclerosis Risk in Communities Study, 1987 to 2010. (A) Neutrophil Count; (B) Lymphocyte Count; (C)
Neutrophil Count/Lymphocyte Count Ratio; (D) Monocyte Count; (E) Eosinophil Count. *Cox proportional hazards model using restricted cubic splines with
knots at the 5th, 27.5th, 50th, 72.5th and 95th percentiles and adjustment for age, race, and sex. The reference is the median value of each white blood cell
differential count (hazard ratio = 1), and the histogram represents the frequency distribution of each white blood cell differential count in the study sample.
doi:10.1371/journal.pone.0136219.g003
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higher neutrophil count/lymphocyte count ratio was also positively associated with AF risk.
No association was identified between eosinophils or basophils and AF. These results did not
differ significantly by race, sex, or age.
These results from the ARIC Study are comparable to the results from recent studies that
were conducted mainly on white populations. The Framingham Heart Study and the Norwe-
gian Tromsø study[14,15] reported a positive association between total WBC count and AF
risk. However, in the Framingham Heart Study, the observed positive association became non-
significant after extending the follow-up period to ten years although the magnitude of the
results were similar to those after 5 years of follow-up.[14] The Tromsø study examined many
systematic inflammatory biomarkers and identified a positive association between total WBC
count and incident AF in the full cohort after a mean follow-up of 10 years and adjustment for
AF risk factors and potential confounders. This study found no association between any of the
WBC differential subtypes and AF, though.[15]
Although both studies reached a similar conclusion in respect to total WBC count and inci-
dent AF, the ARIC study was able to address additional issues raised by the data limitations of
each study. In the ARIC cohort, the positive association between total WBC count and AF
remained present with a longer median follow-up of 21.5 years and adjustment for many AF
risk factors and potential confounders. A racial comparison between whites and African Amer-
icans was possible in our analysis, and no significant interaction by race was identified. In con-
trast to the Tromsø study, the ARIC study had information about prevalent or incident HF, an
important risk factor for AF, and we found significant associations between WBC differential
and AF risk. The larger sample size and statistical power of the ARIC study may have a role in
the differences between studies although further investigation is warranted.
WBC differential, specifically neutrophils, may play a pathophysiological role on the
mechanical pathway between inflammation and AF. Previous evidence suggests that the
enzyme MPO, produced abundantly by neutrophils, may be involved in the development of
atrial fibrosis, resulting in an increased risk of AF.[18,19] Atrial fibrosis is a major component
of the structural remodeling that constitutes the substrate for AF[31], possibly linking inflam-
mation and AF, and eventually leading to the initiation and propagation of AF.[32–34] Matrix
metalloproteinases (MMPs) are enzymes involved in the turnover of extracellular matrix
(ECM) proteins within the atria, a key process in the development of atrial fibrosis. MMPs
have been associated with ECM remodeling in AF,[35] and circulating levels of some MMPs
have been associated with AF risk.[36] MMPs, in turn, have their activity regulated by redox
reactions. Neutrophil-secreted MPOs, through generation of hypocholorous acid, regulate
MMP activity through these redox reactions,[37,38] and, as a result, they affect the pathway
promoting atrial fibrosis and eventually AF. Our results from the ARIC study provide support
for this hypothesis. However, more research is necessary to refine our understanding of this
pathway. In the ARIC study, we also found an inverse association between lymphocyte counts
and AF. To our knowledge, no clear mechanism can explain this association; therefore, further
exploration is needed as to determine if this novel finding is due to chance or if it has patho-
physiological merits.
A major limitation in this analysis is the method of AF ascertainment. Most AF cases were
identified through hospitalization discharges, which omit asymptomatic AF or AF cases man-
aged in outpatient settings. Therefore, under-ascertainment of incident AF may have occurred.
Despite this limitation, the ARIC study and other cohorts have shown acceptable validity of
discharge code-based AF diagnosis.[27,39] In addition, rates of AF in the ARIC cohort are sim-
ilar to those from other population-based studies, improving confidence in the validity of the
AF case ascertainment.[27]
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For the current analysis, we used single baseline measurements of total WBC and differen-
tial counts. These counts may possibly have changed during follow-up, which may not reflect
the total WBC or differential count level immediately preceding an AF event. The results from
the first 10 years of follow-up were similar to those for the entire follow-up period. However,
multiple repeated counts over time may be more relevant and accurate as a predictor of AF.
Also, the ARIC study does not have information on some inflammatory biomarkers, such as
high-sensitivity C-reactive protein, measured at the baseline visit. Results were mostly unaf-
fected after adjustment for available inflammatory biomarkers, such as fibrinogen and albu-
min. Individuals with elevated neutrophil counts linked to ongoing infections were not
excluded due to a lack of information concerning ongoing infections in ARIC at baseline; how-
ever, those who may have had serious ongoing infections at baseline would have most likely
not included in the ARIC study, or the total number would most likely be very low that it
would not explain the association. Any link between elevated neutrophil count due to systemic
inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, or psoriasis
was not examined due to a lack of data on those conditions in ARIC, though the numbers
would also be too low to explain the association. No data was available regarding how long neu-
trophils were elevated at baseline as well. Finally, unmeasured or residual confounding could
also partly explain the observed association through other means such as other systemic
inflammatory biomarkers or diseases not measured in the ARIC study. Despite these limita-
tions, several strengths should be highlighted, including the large, biracial sample with an
extensive follow-up time, a large number of AF events, and comprehensive measurement of
key cardiovascular covariates.
Conclusion
Overall, this study has identified a positive association between high total WBC, neutrophil,
and monocyte counts, separately, with higher AF risk and an inverse association between lym-
phocyte count with AF risk. The positive association between neutrophil count and AF seems
to support the hypothesis that MPO may play a role in the development of atrial fibrosis and
eventually AF. Systemic inflammation may underlie this association and requires further inves-
tigation to examine the specific mechanisms. Future research should also examine the associa-
tion of inflammatory markers with atrial fibrosis in the general population, and the potential
impact of specific anti-inflammatory treatments in reducing AF risk.
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